Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Dendritic cells transfected with hepatocellular carcinoma (HCC) total RNA induce specific immune responses against HCC in vitro and in vivo.

Xie BH, Yang JY, Li HP, Zhang B, Chen W, Zhou B, Peng BG, Liang LJ, He Q.

Clin Transl Oncol. 2014 Aug;16(8):753-60. doi: 10.1007/s12094-013-1145-7. Epub 2013 Dec 12.

PMID:
24338510
2.

Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma.

Li X, Zhang Z, Lin G, Gao Y, Yan Z, Yin H, Sun B, Wang F, Zhang H, Chen H, Cao D.

Tumour Biol. 2016 Aug;37(8):11267-78. doi: 10.1007/s13277-016-4935-z. Epub 2016 Mar 7.

PMID:
26951511
3.

Specific antihepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA.

Zhang L, Zhang H, Liu W, Wang H, Jia J, Si X, Ren J.

Cell Immunol. 2005 Nov;238(1):61-6. Epub 2006 Feb 10.

PMID:
16472793
4.
5.
6.

Induction of cytotoxic T-lymphocyte responses using dendritic cells transfected with hepatocellular carcinoma mRNA.

Peng BG, He Q, Liang LI, Xie BH, Hua YP, Chen ZB, Zhou F.

Br J Biomed Sci. 2006;63(3):123-8.

PMID:
17058712
8.

Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.

Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK.

Ann Surg. 2002 Apr;235(4):540-9.

9.

Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus-associated hepatocellular carcinoma.

Wang H, Feng F, Wang XP, Wang RS, Wu Y, Zhu MG, Zhang H, Zhuang ZX.

Mol Med Rep. 2016 Feb;13(2):1077-82. doi: 10.3892/mmr.2015.4654. Epub 2015 Dec 7.

10.

Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes.

Wang XH, Qin Y, Hu MH, Xie Y.

Cancer Immunol Immunother. 2005 Oct;54(10):971-80. Epub 2005 Jun 18.

PMID:
15965645
11.

Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.

Chen Y, Huang A, Gao M, Yan Y, Zhang W.

Int J Mol Med. 2013 Dec;32(6):1366-72. doi: 10.3892/ijmm.2013.1510. Epub 2013 Sep 27.

PMID:
24085111
13.
14.
15.

Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy.

Han Y, Wu Y, Yang C, Huang J, Guo Y, Liu L, Chen P, Wu D, Liu J, Li J, Zhou X, Hou J.

J Transl Med. 2017 Mar 22;15(1):64. doi: 10.1186/s12967-017-1165-0.

16.
17.
18.
19.

Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.

Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, Gregory SH, Wands JR.

Vaccine. 2015 Mar 3;33(10):1256-66. doi: 10.1016/j.vaccine.2015.01.037. Epub 2015 Jan 25.

20.

Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells.

Sun JC, Pan K, Chen MS, Wang QJ, Wang H, Ma HQ, Li YQ, Liang XT, Li JJ, Zhao JJ, Chen YB, Pang XH, Liu WL, Cao Y, Guan XY, Lian QZ, Xia JC.

Cancer Biol Ther. 2010 Aug 15;10(4):368-75. Epub 2010 Aug 22.

PMID:
20581468

Supplemental Content

Support Center